Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This is a proof-of-concept study which will provide data about the safety and antiviral
activity of several doses of the investigational drug IDX184 given for 3 days in
treatment-naive HCV genotype 1-infected subjects so that optimal doses can be chosen for
testing in later studies.